Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
By Staff Reporters
***
The FDA has reportedly rejected an application from Neuralink.
Recall, Neuralink is Elon Musk’s medical device company to test its brain implants in humans.
LINK: https://neuralink.com/
Neuralink Corporation is an American neurotechnology company that develops implantable brain–computer interfaces (BCIs) based in Fremont, California. Founded by Elon Musk and a founding team of seven scientists and engineers, Neuralink was launched in 2016 and was first publicly reported in March 2017.
Since its founding, the company has hired several high-profile neuroscientists from various universities. By July 2019, it had received $158 million in funding (of which $100 million was from Musk) and was employing a staff of 90 employees. At that time, Neuralink announced that it was working on a “sewing machine-like” device capable of implanting very thin (4 to 6 μm in width) threads into the brain, and demonstrated a system that read information from a lab rat via 1,500 electrodes. They had anticipated starting experiments with humans in 2020, but have since moved that projection to 2023.
Several neuroscientists and publications, including the MIT Technology Review, have been critical of claims made by Musk about Neuralink, calling some of the technological promises “highly speculative”. In March 2023, Reuters reported that the Food and Drug Administration rejected a 2022 application for human trials.
The agency had several concerns, including the risk of tiny wires in the chip shifting to other areas of the brain.
***
COMMENTS APPRECIATED
Thank You
***
Share this:
Filed under: Breaking News, Ethics, Information Technology, Investing, LifeStyle | Tagged: BCIs, brain chips, Brain Computer Interface, elon musk, FDA, implantable brain chips, IT, MIT Review, musk, Neuralink |
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 
Leave a Reply